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Abstract
The liver is an immunologically unique organ containing tolerogenic dendritic cells (DC) that maintain an
immunosuppressive microenvironment. Although systemic IL-12 administration can improve responses to tumors, the
effects of IL-12-based treatments on DC, in particular hepatic DC, remain incompletely understood. In this study, we
demonstrate systemic IL-12 administration induces a 2–3 fold increase in conventional, but not plasmacytoid, DC subsets in
the liver. Following IL-12 administration, hepatic DC became more phenotypically and functionally mature, resembling the
function of splenic DC, but differed as compared to their splenic counterparts in the production of IL-12 following co-
stimulation with toll-like receptor (TLR) agonists. Hepatic DCs from IL-12 treated mice acquired enhanced T cell proliferative
capabilities similar to levels observed using splenic DCs. Furthermore, IL-12 administration preferentially increased hepatic T
cell activation and IFNc expression in the RENCA mouse model of renal cell carcinoma. Collectively, the data shows systemic
IL-12 administration enables hepatic DCs to overcome at least some aspects of the inherently suppressive milieu of the
hepatic environment that could have important implications for the design of IL-12-based immunotherapeutic strategies
targeting hepatic malignancies and infections.
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Introduction
Dendritic cells (DC) are potent antigen presenting cells (APC)
that play important roles in linking innate and adaptive immunity
[1,2,3]. Although bone marrow-derived and splenic DC have been
well characterized in various model systems, the maturation and
functions of DC from the liver remains incompletely character-
ized. The liver is an immunologically unique organ system
constantly exposed to antigens that is also capable of maintaining
an immunosuppressive, or tolerogenic microenvironment
[4,5,6,7]. DC are one of many APC found in the liver that
contributes to this tolerogenic phenotype [6,8]. The liver also
contains a higher proportion of plasmacytoid DC (pDC) to
conventional DC (cDC) compared to other organs such as the
spleen where there is a greater abundance of cDC compared to
pDC [5,9,10,11]. Since hepatic pDCs have been implicated in
maintaining oral tolerance [12], the overall ratio of cDC:pDC
could be very important in the regulation of adaptive immune
responses in the liver. Previous studies have shown hepatic DC
express lower levels of costimulatory and MHC class II molecules,
have reduced cytokine expression and induce minimal T cell
proliferation [5,9,10,11,13]. Taken together, these characteristics
of hepatic DC render them a critical component of the inherently
immunosuppressive liver microenvironment.
The goal of this study was to investigate whether immunother-
apeutic regimens have the potential to overcome the immunosup-
pressive phenotype of DC in the liver. The reversal of DC from a
tolerogenic state to one more closely associated with effector
immune responses might hold considerable promise for the
treatment of cancers in the liver. One highly promising
immunotherapeutic agent is IL-12, a hetero-dimeric cytokine
mainly expressed by phagocytes and DC which leads to natural
killer (NK) cell activation and the differentiation of T cells towards
a T helper 1 (Th1) phenotype, linking innate and adaptive
immunity [14,15]. IL-12 is an attractive candidate, either as a
single agent or in combination with other cytokines/immuno-
modulatory agents, for cancer immunotherapy based upon its
potent antitumor effects observed in various preclinical models
[16,17]. Numerous studies have used either systemic or localized
IL-12 administration (such as fibroblasts that have been genetically
modified to produce IL-12) [18] to further potentiate the immune
response and enhance innate and adaptive immunity. However,
the effects of systemically administered IL-12 on DC populations,
in particular hepatic DC, have not been examined and such
studies can be instructive for understanding overall immune
function in this unique anatomical compartment.
In this study, we demonstrate that in vivo IL-12 administration
improves the effector functions of hepatic DC populations to levels
which are comparable to splenic DC. Following systemic IL-12
administration, the number of specific hepatic DC subsets increase
and are phenotypically and functionally more mature. Further-
more, IL-12 administration enabled hepatic DC to robustly
increase T cell activation and proliferation. Our study demon-
strates the potential for systemic IL-12 treatment to modulate
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33303hepatic DC and suggests the potential for IL-12 based therapies to
provide enhanced immune activation in the liver, which is often an
immunosuppressive microenvironment.
Results
Systemic IL-12 administration expands hepatic and
splenic DC
Our previous studies involving systemic administration of IL-12
in BALB/c mice showed repeated daily administration during a
cycle of treatment at specific doses is well tolerated [19,20]. Daily
systemic administration of 1 mg IL-12 into BALB/c mice results in
an increase in DC (NKp46
2CD11c
+Class II
+) present in the
spleen and liver, observed as early as day 4 and reaching a
maximum at day 7 (Figure 1A and B, respectively), that gradually
declines to homeostatic levels by day 11. Interestingly, the absolute
number of hepatic DC remained approximately 1/10
th of the
absolute number of splenic DC regardless of the treatment.
Careful analysis was performed to exclude the confounding
NKp46
+ NK cells, as basal expression levels of CD11c on the
NK cells significantly increased following IL-12 treatment (Figure
S1) [21,22]. In addition, reduced bone marrow cellularity was
observed following IL-12 administration (data not shown),
suggesting the bone marrow as a contributing source for the
observed increase in DC.
Next, we analyzed the different subsets of splenic and hepatic
DC at day 4 following systemic administration of IL-12. For
comparability between DC subset populations in the spleen and
liver, the following subsets were analyzed: cDCs broken into
CD11b
+ DC (defined as NKp46
2CD11c
+ Class II
+ CD11b
+
CD8a
2; Figure S2), CD8a DC (defined as NKp46
2 CD11c
+
Class II
+ CD11b
2 CD8a
+; Figure S2), and pDC (defined as
CD11c
int Class II
+ B220
+ Siglec H
+ PDCA-1
+; Figure S3)
[9,13,23,24]. The cDC subsets consisting of both the CD11b
+
and CD8a
+ DC, were significantly increased in both the spleen
and liver (Figure 1C). In the liver, a respective 3.6 fold and 1.8 fold
increase in the numbers of CD11b
+ and CD8a
+ cDC was
observed following IL-12-treatment. On the other hand, the
number of hepatic pDC, which comprise the major DC subset in
the liver, remained unchanged despite the increase in the number
of liver leukocytes following IL-12 administration, in contrast to
the increase observed within the spleen (Fig. 1C). Thus, IL-12
treatment increases the ratio of cDC to pDC in the liver while the
ratio remains the same in the spleen, despite equivalent increases
across the different splenic DC populations. Given that hepatic
pDC have been implicated in maintaining oral tolerance [12] and
the absolute numbers remain consistent while cDC increase, this
suggests IL-12 administration could alter the immunological status
of the liver microenvironment.
IL-12 treatment matures hepatic DC
Since systemic IL-12 administration had dramatic effects on DC
numbers in the liver, we hypothesized that the maturational state
of these DC might also be enhanced. Under basal conditions, the
combined population of hepatic DC subsets from vehicle control
(VC)-treated mice generally expressed lower basal levels of co-
stimulatory molecules compared to their splenic DC counterparts,
consistent with the belief that hepatic DCs are in a relatively
immature state compared to their splenic counterparts [13,24].
Following IL-12 therapy, however, the cDC and pDC populations
in the spleens (Figure 2A) and livers (Figure 2B) of mice treated
with IL-12 displayed significant increases in the cell surface
expression of the co-stimulatory molecules CD40, CD80 and
CD86, as compared to VC treated mice. It is noteworthy that
splenic and hepatic cDCs demonstrated a greater change in the
expression pattern of the costimulatory molecules than did splenic
and hepatic pDC. Furthermore, studies utilizing SCID mice
(which lack T cells but retain NK cells) and IL2Rgamma(c) (cc)
knockout mice (which have limited mature T cells and lack NK
cells) indicate that the maturation of the DCs seen with systemic
IL-12 is partially dependent upon NK cells but not on T cells
(Figure S4). Overall, the potential for IL-12 administration to
increase the expression of CD40, CD80 and CD86 on hepatic
cDC and pDC, to levels similar to or higher than the levels
detected on splenic DC subsets, supports the conclusion that IL-12
substantively enhances the cellular maturation of hepatic DC.
IL-12 treatment reduces antigen uptake and processing
in DC
Since antigen uptake by DC is elevated in immature cells and
reduced upon cell maturation, we next measured the antigen
uptake and processing capabilities of hepatic DC following IL-12
therapy. Using flow cytometry to quantitate fluorescence produced
by the uptake and processing of DQ
TM Ovalbumin (DQ-OVA),
we observed a dramatic decrease in the DQ-OVA MFI after IL-12
administration in both splenic cDC and pDC (Figure 3A). The
DQ-OVA MFI in splenic cDC was reduced from 2528697 to a
MFI of 9116351 with IL-12 therapy. Hepatic DC from IL-12
treated mice also displayed similar functional properties of antigen
and processing capabilities of DQ-OVA. Following IL-12
treatment, hepatic cDC had a significant reduction in the MFI
of DQ-OVA from 32046417 to 17966556, indicating DC
maturation (Figure 3B). Hepatic pDC from IL-12 administered
mice also showed a significant decrease in antigen uptake and
processing capabilities of DQ-OVA. Representative contour plots
are shown in Figure S5, demonstrating the increased maturation
and reduced uptake and processing capabilities of the antigen by
co-staining the DC subsets with CD80 following incubation with
DQ-OVA. It is also worth noting that the antigen uptake by
hepatic DC from VC-treated mice was higher compared to splenic
DC from VC-treated mice potentially indicative of the immature
state of hepatic DC relative to their splenic counterparts under
basal conditions. Collectively, the increased expression of the co-
stimulatory molecules and the decreased antigenic uptake by the
both cDC and pDC subsets indicate systemic IL-12 therapy results
in the maturation of DC, with a substantial net change among
hepatic DC.
In vivo administration of IL-12 primes hepatic DC to
respond to ex vivo TLR agonist stimulation
DC express a variety of pattern recognition receptors, which
include TLRs capable of responding to pathogen-associated
molecular patterns. A previous study showed the production of
IL-12 by splenic and bone marrow-derived DC initiates a
feedback loop by reducing subsequent IL-12 production, thereby
limiting the Th1 polarizing immune response [25]. We hypoth-
esized that systemic IL-12 administration may render hepatic DC
more responsive to TLR agonist-mediated activation. To test this,
bulk leukocytes from the spleen and liver of VC or IL-12-treated
mice were stimulated ex vivo with either poly(I:C) (TLR3), LPS
(TLR4) and CpG (TLR9) and intracellular IL-12 production was
analyzed on gated cDC populations. Stimulation of splenic cDC
from IL-12 treated mice with the TLR agonists revealed only a
modest increase in the percentage of splenic cDC expressing
intracellular IL-12p40 (Figure 4A and S6A), whereas significantly
increased levels of IL-12p40 were detected in hepatic cDC
following stimulation (Figure 4B and S6A). Interestingly, the basal
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stimulation was higher in VC-treated hepatic cDC compared to
splenic cDC (Figure S6A). The expression levels of IL-12p40, as
detected by intracellular staining, in the pDC subsets following
TLR stimulation was minimal, with the exception of CpG
stimulation (data not shown). The detection of intracellular IL-
12p40 may reflect the formation of either IL-12p40 homodimers,
or heterodimers with the p35 subunit, forming IL-12p70, or with
the p19 subunit, forming IL-23. To further delineate between
these possibilities, ELISAs were performed to measure total IL-
12p40 (Figure 4C) and IL-12p70 (Figure 4D). The levels of IL-23
and IL-27 (p35/EBV-induced gene 3 [EBI3] subunits), as
measured by ELISA, in these culture supernatants were below
the limits of detection (data not shown). For hepatic DC, the
increase in IL-12p40 detected by ICS and ELISA also had a
similar trend for increased IL-12p70 expression (Figure 4C).
Interestingly, despite differences observed in IL-12 expression
levels between splenic and hepatic DC, TNF expression levels
remained comparable between systemic IL-12 and VC-treated
mice (Figure 4E), although the levels of IL-6 were dramatically
elevated in hepatic DCs from TLR-agonist stimulated DCs (Figure
S6B). Taken together, these findings demonstrate that exogenous
IL-12 administration has the potential to render hepatic DC more
responsive to TLR stimulation with altered pro-inflammatory
cytokine production that may contribute to enhancing Th1
immune responses.
IL-12 treatment enhances the T cell proliferative
capability of hepatic DC
Since our studies outlined above revealed that IL-12 treatment
increased DC phenotypic and functional maturation, we sought to
determine whether IL-12 treatment could overcome the inherently
lower T cell stimulatory capacity of hepatic DC in T cell
proliferation assays. As shown in Figure 5A, hemagglutinin (HA)-
peptide pulsed splenic DC have at least a 3 fold higher T cell
proliferative capability compared to hepatic DC in stimulating
Figure 1. Increased splenic and hepatic DC numbers following systemic IL-12 treatment. BALB/c mice were treated with 1 mg/mouse IL-
12 (solid square) or vehicle control (VC; open triangle) for 4 consecutive days from day 0, as indicated with arrows, then leukocyte populations
analyzed at various days post treatment. The total DC number (NKp46
2CD11c
+ Class II
+), is shown for the spleen (A) and for the liver (B). The results
shown are the mean 6 SD from 3–5 mice/group at each time point and representative of 3 separate experiments. (C). Differences in DC subsets were
examined in the spleen and liver at day 4 for CD11b
+ (NKp46
2CD11c
+Class II
+CD11b
+), CD8a
+ (NKp46
2CD11c
+Class II
+CD8a
+), and pDCs
(NKp46
2CD11c
+Class II
+B220
+mPDCA-1
+SiglecH
+), respectively. Shown is the mean 6 SD from 4–5 mice/group and representative of more than 3
independent experiments. *, p,0.05; **, p,0.01; ***, p,0.001; Mann Whitney U test.
doi:10.1371/journal.pone.0033303.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33303Figure 2. Systemic IL-12 treatment leads to an increase in costimulatory molecule expression on DCs. Mice were treated with one cycle
of IL-12 or vehicle control (VC) administration. Leukocytes were harvested the following day from the spleen and liver and the DC populations were
analyzed by flow cytometry for expression levels of CD40, CD80 and CD86. The cDC (NKp46
2CD11c
+Class II
+ mPDCA-1
2 including both CD11b and
CD8a DCs) and pDC (NKp46
2CD11c
+Class II
+B220
+mPDCA-1
+) in the spleen (A) and liver (B). A representative histogram from one individual mouse is
shown with 3–6 mice/group in an experiment that has been repeated in more than 3 independent experiments with similar results. Shaded line is the
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previous reports demonstrating substantially reduced stimulatory
capacity of hepatic DC compared to their splenic counterparts
[13,26]. In mixed lymphocyte reactions, comparable proliferative
responses from naı ¨ve C57BL/6 (H-2
b) responder T cells were
observed using allogeneic BALB/c (H-2
d) stimulator splenic DCs
from either IL-12 or VC-treated mice (Figure 5B). Hepatic DC
from VC-treated mice showed a 2-fold lower allo-proliferative
response compared to their splenic DC counterparts, consistent
with the conclusion that hepatic DC have reduced immunosti-
mulatory capabilities [27]. After systemic IL-12 pretreatment,
isolated hepatic DC demonstrated greater T cell proliferation
capability at the higher stimulator: responder ratios (from 1:2 to
1:10 DC:T cell ratio) compared to hepatic DC from VC-treated
mice (Figure 5B). Indeed, the amount of alloreactive T cell
proliferation observed with hepatic DC from IL-12 treated mice
trended towards the functional stimulatory capacity of splenic DC,
on an equivalent per cell basis.
To further determine the effects of IL-12 administration on T
cell proliferative capacity, we utilized the transgenic TCR-HA
specific mouse model. As shown in Figure 5C, ex vivo cultured
splenic HA-peptide-pulsed DC from in vivo IL-12 treated mice
isotype control and the black solid line is the stain for the respective treatment. The MFI of the corresponding population is shown in the upper right
corner of each histogram.
doi:10.1371/journal.pone.0033303.g002
Figure 3. Decreased antigen uptake by splenic and hepatic DCs following systemic IL-12 treatment. Leukocytes from IL-12 or vehicle
control treated mice were incubated with 100 mg/ml DQ-OVA for 30 min at 37uC and analyzed by flow cytometric analysis gating on cDC
(NKp46
2CD11c
+Class II
+) and pDCs (NKp46
2CD11c
+Class II
+mPDCA-1
+) populations in the spleen (A) and liver (B). Left hand shows a representative
histogram sample for an individual mouse displaying the antigen uptake and processing of DQ-OVA by cDC or pDCs (solid line). The shaded line is
the respective isotype control. The MFI of a representative sample is shown in the upper right corner of each histogram. The right side graphically
displays the mean 6 SD of the DQ-OVA MFI from an independent experiment with 3–5 mice/group that has been repeated 3 times with similar
results. *, p,0.05; Mann-Whitney U test.
doi:10.1371/journal.pone.0033303.g003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33303Figure 4. Altered cytokine expression profile of splenic and hepatic DCs. Bulk lymphocytes from the spleen and liver were incubated with
media alone (no treatment; no Tx), 25 mg/ml poly(I:C), 1 mg/ml LPS or 2.5 mg/ml CpG for 18 hours. Splenic DC (A) and hepatic DC (B) populations were
gated and intracellular IL-12p40 expression examined by flow cytometric analysis. Shown is a representative sample from an individual mouse in an
independent experiment repeated 3 times (3–5 mice/group). Purified splenic and hepatic DC pooled from 5–15 mice were cultured under the same
conditions and culture supernatants harvested 48 hours later. Cytometric bead array was performed to detect in the supernatants the levels of IL-
12p40 (D), IL-12p70 (D) and TNF (E) from splenic DC and hepatic DC. The bar graph displays the mean 6 SEM expressed in pg/ml per 10
6 cells derived
from the pooled data obtained from 3 independent experiments. *, p,0.05 (Mann Whitney U Test).
doi:10.1371/journal.pone.0033303.g004
Figure 5. Enhanced T cell proliferation from hepatic DCs following systemic IL-12 treatment. (A) Differential HA TCR proliferation of naı ¨ve
splenic and hepatic DC. Purified DC were peptide pulsed and incubated with 2610
4 HA-TCR T cells at a 1:1 ratio for 72 hours and 1 mCi of
[
3H]thymidine added during the last 18 hours of culture. (B) Allogeneic mixed lymphocyte reaction. Purified splenic and hepatic DCs from BALB/c
mice (H-2
d) were cultured at differing DC:T cell ratios with 1610
5 purified T cells from C57BL/6 mice (H-2
b) for 72 hours with 1 mCi of [
3H]thymidine
added during the last 18 hours of culture. (C) HA TCR Tg model. Purified splenic and hepatic DCs were pulsed with varying doses of HA peptide for
2 hours then cultured with 2610
4 HA-TCR T cells at a 1:1 ratio for another 72 hours. 1 mCi of [
3H]thymidine was added to each well during the last
18 hours of culture. Shown is the mean 6 SD done in quadruplicates from one of three independent experiments. *, p,0.05; **, p,0.01; *** p,0.001;
Student’s T test.
doi:10.1371/journal.pone.0033303.g005
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HA peptide concentrations, as compared to VC-treated mice.
These results correlated with a similar pattern of T cell proliferation
utilizing splenic DC in the allogeneic MLR (Figure 5B). On the
other hand,HApeptide-pulsedhepaticDC,containinga mixture of
the cDC and pDC subsets, from IL-12 treated mice induced
significantly greater T cell proliferation compared to DC from VC-
treated mice at all HA peptide concentrations (Figure 5C). An
analysis of the specific contributions that each DC subset made to
the T cell proliferative response revealed that hepatic pDCs from
IL-12 treated mice induced significant fold increase in HA T cell
proliferation compared to VC, on an equivalent cell basis (Figure
S7). In the spleen, the cDC subset was the likely subset contributing
to any enhanced proliferative response seen (Figure S7). The data
obtained in this series of T cell proliferation assays indicates that IL-
12 therapy may further alter their functional capacity to overcome
the reduced proliferative state inherent with hepatic DCs, thus
resulting in a greater T cell proliferative response on a per cell basis.
IL-12 therapy enhances hepatic T cell activation in vivo in
RENCA-tumor bearing mice
The hepatic microenvironment contains a variety of regulatory
factors and cells that can dampen local immune responses.
Therefore, we next examined whether the phenotypic and
functional changes induced by IL-12 in hepatic DCs would also
contribute to the in vivo modulation of T cell mediated antitumor
responses. For these studies, we utilized the RENCA orthotopic
murine renal cell carcinoma model whereby the primary tumor
readily metastasizes to the lungs, liver and regional lymph nodes.
We have previously shown antitumor immunity using IL-12-based
treatment regimens that are dependent upon NK and CD8
+ T
cells [19,28,29]. For these studies, orthotopic RENCA-bearing
mice were treated with 2 cycles of IL-12 as outlined in Figure 6A.
Following two cycles of IL-12 treatment, a significant decrease in
tumor burden was noted through decreased weight of the primary
tumor (Figure 6B), consistent with our earlier results [19,28].
Equivalent increases in DC numbers were observed in tumor
bearing (TB) mice following IL-12 therapy, as compared to naı ¨ve,
non tumor-bearing (non-TB) mice (data not shown). Interestingly,
CD3
+DX5
- T cells obtained from the spleen and liver following
IL-12 treatment revealed organ-specific T cell activation patterns.
Splenic CD4
+ and CD8
+ T cells showed no differences in
expression of the early activation marker, CD69, between IL-12
treated and VC-treated mice (Figure 6C). In marked contrast,
hepatic CD4
+ and CD8
+ T cells had significantly higher CD69
expression in IL-12-treated mice compared to VC-treated mice
(Figure 6C). Interestingly, the activation of hepatic T cells was not
completely dependent upon the presence of RENCA, because
non-TB mice also showed a similar activation of hepatic T cells
with IL-12 therapy. Furthermore, while there were no substantial
changes in the CD44
hi population of splenic CD4
+ and CD8
+ T
cells detected (Figure 6D), an increased percentage of CD44
hi
hepatic CD4
+ and CD8
+ T cells (Figure 6D) mirrored the CD69
expression pattern (Fig. 6C), and was inversely proportional to the
percentage of CD62L
hi expressing T cells (data not shown). These
findings highlight the potential for IL-12 administration to
potently activate hepatic T cells and further contribute to the
overcoming of inherent immunosuppression in the liver.
A hallmark function of DC is their ability to induce antigen-
specific T cells. To date, no defined tumor antigen has been
identified on RENCA cells; therefore, an indirect assay to
quantitate IFNc expression was established using culture super-
natants of purified splenic and hepatic T cells co-cultured with
irradiated RENCA tumor cells (Figure 6E). Splenic T cells from
RENCA-bearing mice treated with IL-12 produced IFNc to levels
similar to T cells obtained from VC treated mice (0.38 ng/ml
versus 0.43 ng/ml, respectively). In contrast, the co-culture of
purified hepatic T cells from RENCA-bearing mice treated with
IL-12 induced 4.2 ng/ml IFNc as compared to 0.4 ng/ml from
hepatic T cells obtained from VC-treated mice. Meanwhile, the
expression of IL-10 was minimally induced in the spleen co-
cultures while low levels of IL-10 were detected in the hepatic T
cell co-cultures, regardless of treatment with IL-12 (Figure 6F).
Surprisingly, the treatment with IL-12 further increased the
amount of IL-10 produced from the T cells in comparison to the T
cells co-cultured from the VC group, but the fold increase was not
as substantial as observed for IFNc production. Taken together,
these results show systemic administration of IL-12 specifically
enhances the activation of hepatic T cells, but not splenic T cells,
which leads to the further development of IFNc+ T cells in a
RENCA tumor-dependent manner.
Discussion
The liver microenvironment has the distinctive ability to
provide seemingly disparate roles in both the formation of a
tolerogenic environment that is essential for controlling the
development of undesirable immune responses such as orally
ingested food antigens, as well as the maintenance of immunore-
active functions frequently associated with lymphoid organs [7,30].
Alterations to specific hepatic cell populations, induced by
therapeutic response of drugs or exposure to pathogenic organisms
such as hepatitis virus and tumors, may help to explain some
aspects of this complex environment. Resident hepatic DC have
been implicated in mediating tolerance and immune suppression
within this microenvironment [8,12,27]. A more refined under-
standing of the cellular changes particularly that of hepatic DC
compartments, would be valuable for the development of
improved strategies that generate more durable adaptive immune
responses or the inhibition of potentially detrimental responses in
cases of autoimmunity and liver transplantations [31,32]. In this
study, we demonstrate that systemic IL-12 administration not only
increased the number of cDC present but more importantly, that
these cells were phenotypically and functionally more mature, and
more capable of eliciting effective T cell proliferation. The
dramatic capability for systemic IL-12 treatment to modify the
phenotype and functional activity of hepatic DC to more closely
resemble splenic DC, at least under in vitro conditions, thus
highlights the potential for IL-12 based therapies for therapy of
liver disease.
One of the challenges to studying DC biology in the liver is the
relative paucity of resident hepatic DC. Several groups have
addressed this issue by expanding the number of DC in vivo
through the delivery of GM-CSF and/or Flt3-L [24,26,33],
allowing for the expansion of cDC and pDC, respectively [34]. We
opted not to expand the cells within the liver using these methods
prior to administering IL-12 as these approaches would likely alter
the homeostatic balance of DC and potentially other cells within
the local microenvironment [35] and thus not provide represen-
tation of the suppressive nature within the liver. Indeed, the
homeostatic ratio of cDC:pDC in each organ may profoundly
contribute to the nature of the ensuing immune responses. Since
pDC in the liver have been shown to suppress immune responses
[12,13]. the analysis of the cDC:pDC ratio has become a valuable
parameter for the evaluation of the clinical success of patient
transplantations [36,37] and autoimmune disorders [38]. Main-
taining the balance of hepatic DC subsets is essential, as
exemplified by chronic inflammation and the resulting hepatic
Altering Liver DC Function with IL-12 Therapy
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conditions, the homeostatic ratio of cDC:pDC in the spleen is
relatively high in dramatic contrast to the liver where we show pDC
to comprise the major DC subset.. Following IL-12 treatment,
however, we demonstrated the cDC:pDC ratio within the liver
rapidly increased as a result of significant cDC expansion and
eventually decreased following the cessation of IL-12 administra-
tion. The cDC:pDC ratio in the spleen, however, remained
relatively unaffected by IL-12 treatment. The IL-12 mediated
increase in cDC:pDC ratio of the liver may thus contextually
provide the appropriate conditions to mount more robust immune
responses as increased DC maturation was also observed.
IL-12 binds to the complex of IL12Rb1 and IL12Rb2 subunits
expressed on T cells and NK cells [14]. DC have also been shown
to express both of these subunits [40,41]. The maturation of the
DCs which we describe may therefore be due to direct interactions
between the administered IL-12 and its receptor expressed on the
DC or through indirect mechanisms. In the latter regard, it has
been reported that maturation of hepatic DC were dependent
upon the activation of NKT cells through either administration of
alpha-galactosylceramide (aGalCer) or through infection with
MCMV [11]; however, mature DC, based upon co-stimulatory
expression, were still observed following IL-12 administration to
CD1d knock-out mice, which developmentally lack NKT cells (our
unpublished observations). On the other hand, treating IL2R-
gamma(c) mice, which lack NK and mature T cells, with systemic
IL-2 did not result in DC maturation in the spleen and liver,
whereas DC maturation was observed with IL-12 administration
in SCID mice, consistent with the observations seen in wild-type
mice (Figure S4). The reciprocal crosstalk communication between
NK and DCs has been the subject of considerable investigations
[42,43,44], and we surmise that cellular interactions may play a
significant role in the DC activation phenotype observed. Studies
involving the selective transient depletion of cDC in CD11c-
Figure 6. Hepatic T cells are differentially modulated compared to splenic T cells following IL-12 therapy in RENCA tumor bearing
mice. (A) Schematic of the treatment cycle for orthotopic RENCA tumor bearing mice, where mice were injected with 1610
5 RENCA cells into the
kidney capsule then treated with two cycles of IL-12 or VC injections. (B) Mice were euthanized on day 13 following treatment and the weight of the
primary tumor was recorded. The activation of CD4 and CD8 T cells (CD3
+DX5
2) from the spleen and liver of VC (white) and IL-12 (black) treated
RENCA tumor-bearing and VC (grey) and IL-12 (striped) treated non-tumor bearing mice is shown through expression of CD69 (C) and CD44high (D)
Shown is the mean 6 SEM from two independent experiments with 5 mice/group in each experiment. Purified splenic and hepatic T cells pooled
from 2–5 mice/group from RENCA tumor-bearing mice were co-cultured with irradiated RENCA at a 10:1 ratio for 96 hours followed by IFNc detection
E) and IL-10 (F) in the culture supernatants. The bar graphs represent the means 6 SD assayed in triplicate. Shown is a representative experiment that
has been repeated twice with similar results. NS not significant, **p,0.01; *** p,0.001; Mann Whitney U test.
doi:10.1371/journal.pone.0033303.g006
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express the diphtheria toxin receptor and GFP in CD11c
hi cells,
may provide detailed mechanism in some instances. Unfortunate-
ly, the determination of the contributing cellular effects in vivo with
IL-12 therapy would likely be confounded by the promiscuous
expression of CD11c in activated NK cells following IL-12
treatment. In this instance, a population of the NK cells would
become sensitive to diphtheria toxin-mediated elimination, by
means of non-specific expression of the diphtheria toxin receptor
and GFP on NK cells following IL-12 treatment (Figure S1 and
our unpublished observations).
The liver has been classically thought to harbor dying T cells as
a mechanism for removing them from the lymphatic system.
Crispe and colleagues however demonstrated that activated T cells
within the liver remain functional, expand and secrete IFNc and
potentially mediate effector activities in lymphoid organs [46,47].
It is currently unknown whether the activated T cells observed in
our study are derived from systemically activated T cells that
subsequently become trapped in the liver [48] or if these represent
intrahepatic-derived T cells [49]. Supporting the latter point,
hepatic DC from IL-12-treated mice were capable of inducing
strong T cell proliferation in vitro, similar to that seen with splenic
DC, on a per cell basis. Our data demonstrates that systemic IL-12
administration alters the hepatic DC subset composition and
induces DC maturation, in turn resulting in further T cell priming
of naı ¨ve cells. Further supporting this, a significant proportion of
activated hepatic T cells, based upon expression of CD69 and
CD44
hi, were present in both RENCA-tumor and non-tumor
bearing mice and high levels of IFNc were detected in the
supernatants of hepatic T cell from RENCA tumor-bearing mice
co-cultured with RENCA cells compared splenic T cells under
similar conditions. Based upon these collective findings, future
studies utilizing a hepatocellular tumor model system may provide
an opportunity to assess the contributing role that DC have in
altering the T cell responses in the hepatic microenvironment
during tumor development and progression. Additionally, further
studies on the fate and function of the activated T cells after
cessation of IL-12 within the liver may provide additional novel
insight into the design of localized therapeutic strategies to
maximize immune responses against intra-hepatic tumors or
infectious pathogens that target the liver.
Overall, our findings demonstrate that systemic IL-12 admin-
istration alters the balance of hepatic DC favoring the generation
of an immune response. Splenic DC have an inherently greater
stimulatory capacity and maturational state compared to resident
hepatic DC. Following systemic IL-12 administration, hepatic DC
become more mature and acquire a significantly greater capacity
to stimulate T cells and increased cytokine production as
compared to their splenic DC counterparts. Collectively, IL-12
treatment alters the hepatic microenvironment by enhancing the
function of resident hepatic DC and provisionally providing an
opportunity to overcome a component of the inherently
suppressive milieu of the hepatic microenvironment. Our data
suggests that modifying hepatic DC function might be further
exploited with biological response modifiers as a mean to develop
new strategies, either systemically or locally, for targeting hepatic
malignancies and infections.
Materials and Methods
Animals
BALB/c and C57BL/6 mice (6–12 weeks old) were obtained
from Jackson Laboratories (Bar Harbor, ME). The T cell receptor
HA transgenic mice, specific for peptide 518–526 of HA, were a
gift from Dr. Tom Sayers (NCI/NIH), and originally obtained
from Dr. Linda Sherman (The Scripps Research Institute, La
Jolla, CA). SCID and IL2Rgamma(c) mice were generously
provided by Drs Howard Young (NCI/NIH) and Dan McVicar
(NCI/NIH), respectively. All mice were housed under pathogen-
free conditions in animal facilities located at the NCI (Frederick
MD), following the guidelines in accordance with protocols (#07-
068 and #10-256) approved by the NCI-Frederick Animal Care
and Use Committee.
Treatment protocol
Recombinant murine IL-12 was from Peprotech (Rocky Hill,
NJ). Mice were injected intraperitoneally (i.p.) for one cycle, unless
otherwise stated, with either vehicle control (VC; HBSS containing
0.1% normal mouse serum) or with 1 mg IL-12 for 4 consecutive
days. Mice were euthanized between days 4 and 7 after the start of
treatment, unless otherwise stated, and the livers and spleens
harvested.
Liver and spleen leukocyte isolation
Liver leukocytes were isolated as previously described [28] with
a few modifications. After flushing with HBSS, the liver was
minced and incubated with 1 mg/ml Collagenase D (Roche
Diagnostics, Indianapolis, IN) in RPMI media (Mediatech,
Manassas, VA) at 37uC for 30 min then further disrupted using
a Stomacher 80 (Seward, West Sussex, United Kingdom) system
in HBSS supplemented with 2 mM EDTA and 0.1% BSA. Liver
nonparenchymal cells were collected by centrifugation at 3256g
for 10 min at 4uC, washed with cold HBSS, and centrifuged. The
cell pellet was resuspended in 40% Percoll (Amersham Pharmacia,
Piscataway, NJ) then underlaid with 80% Percoll and centrifuged
for 25 min at 8506g. All Percoll solutions were prepared as 16
DPBS/Percoll diluted with DMEM (Mediatech). Leukocytes were
collected at the interface and washed twice in HBSS.
Spleens were incubated in Collagenase D (1 mg/ml) for 30 min
at 37uC. Splenocytes were prepared by mechanical disruption
followed by treatment with ACK lysis buffer (Invitrogen, Grand
Island, NY). Leukocyte counts were obtained using a Sysmex KX-
21 analyzer (Mundelein, IL). Splenic and hepatic DC were isolated
using DX5 microbeads (Miltenyi Biotec, Auburn, CA) for NK cell
depletion followed by positive selection of DC using CD11c
microbeads according to manufacturer’s protocol (Miltenyi
Biotec). DC were further purified by sorting on a FACSAria
(Becton Dickinson) with .95% purity.
Analysis of cell phenotype by flow cytometry
All antibodies utilized were purchased from either BD Biosci-
ences (San Jose, CA) or eBiosciences (San Diego, CA). The
following fluorescently-labeled or biotinylated antibodies were
utilized: CD11c (HL3, N418), MHC Class II (M5/114.15.2),
CD40 (HM40-3), CD80 (16-10A1), CD86 (GL1), B220 (RA3-6B2),
CD11b (M1/70), CD49b (DX5), Siglec H (eBio440c), PDCA-1
(eBio927), NKp46 (29A1.4), CD44 (IM7) and CD69 (MEL-14). All
samples were incubated 30 min on ice with 2.4G2 ascites fluid to
block Fcc receptor binding before adding fluorochrome-conjugated
antibodies. Flow cytometric data was collected on a BD FACSort
and LSRII flow cytometers (BD Biosciences) and analyzed using
FlowJo 7.5 software (Treestar; Ashland, OR).
Cytokine expression
Bulk splenic and hepatic leukocytes were prepared as described
above and cells were cultured in complete RPMI media. Cells
were stimulated with either 25 mg/ml poly(I:C) (Sigma; St. Louis,
Altering Liver DC Function with IL-12 Therapy
PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e33303MO), 1 mg/ml LPS (Sigma) or 2.5 mg/ml CpG, containing an
equimolar combination of phosphorothiate ODNs 1555 (GCTA-
GACGTTAGCGT) and 1466 (TCAACGTTGA), a kind gift from
Dr. Dennis Klinman, (NCI/NIH) [50] and incubated for 12 h
under standard conditions with 1 ml/ml GolgiPlug (BD Biosci-
ences) added to the cultures for the last 10 h. Cells were harvested
and Fcc receptors were blocked using 2.4G2 prior to staining for
specific DC populations. Cells were washed then fixed with BD
Cytofix/Perm solution followed by intracellular staining with IL-
12p40 (C15.6) and TNFa (MP6-XT22) antibodies in BD Perm/
Wash solutions. Purified DC were obtained according to
manufacturer’s protocol (Miltenyi Biotec) and cultured in media
containing 20 ng/ml GM-CSF (Biosource; Camarillo, CA) with
the TLR agonists indicated above. Culture supernatants were
harvested 48 h later and analyzed for cytokine expression using a
proinflammatory cytometric bead array (CBA; BD Biosciences) on
a BD FACScan cytometer (BD Biosciences) or by standard
ELISAs (eBioscience).
Antigen uptake assays
Isolated leukocytes were incubated for 30 minutes at 37uC with
100 mg/ml of DQ
TM Ovalbumin (DQ-OVA; Molecular Probes,
Eugene, OR) in RPMI media. Cells were harvested, washed four
times with ice-cold HBSS then stained and gated on specific DC
populations by flow cytometry analysis. Cells that uptake and
process antigen were determined by green fluorescence occurring
when DQ-OVA undergoes proteolytic degradation during antigen
processing.
T cell proliferation assays
Mixed allogeneic reactions were performed using varying doses
of irradiated BALB/c splenic and hepatic DCs (3000 rads)
cocultured with 10
5 purified T cells from C57BL/6 mice using
Pan T cell microbeads (Miltenyi Biotec). The HA-specific T cell
culturing conditions utilized a 1:1 ratio of irradiated DC to purified
HA T cells. DCs were pulsed with the HA peptide (IYSTVASSL)
generously provided by Dr. Tom Sayers, (NCI/NIH) [51] at
varying doses for 2 h then co-cultured with purified HA-TCR T
cells. Co-cultures were incubated at 37uC for 72 h in 96 well U-
bottom plates (Costar; Corning, NY), with 1 mCi [
3H]thymidine/
well added during the final 18 h of culture. Cells were harvested
onto a filtermat and the amount of
3H incorporation was
determined using a Wallac 1450 microbeta counter (Perkin Elmer).
All counts per minute(cpm) displayedwerecorrectedby subtracting
the incorporation amount from media alone. Background values, of
T cells only, were below 3000 cpm.
Tumor model and assaying T cell function
BALB/c mice were injected orthotopically into the kidney
capsule with 10
5 RENCA cells [19]. After 11 days, mice were
treated with two cycles of IL-12 treatment with a 3 day rest between
cycles.Micewereeuthanized after 2 cyclesofIL-12 andtheprimary
tumors were measured and weighed. T cells from livers and spleens
were phenotyped by flow cytometric analysis. T cells obtained from
the spleen and liver were column purified using a negative selection
method (Miltenyi), then co-cultured with irradiated RENCA cells
(12,000 rads) at a ratio of 10:1 in complete RPMI media. Culture
supernatants were harvested 96 h later and IFNc expression levels
were measured by Cytometric Bead Array (BD Biosciences).
Statistics
Data were analyzed using Prism 5 (GraphPad Software Inc; La
Jolla, CA) utilizing the Student’s t test or the non-parametric
Mann-Whitney U-test where appropriate. P values,0.05 were
considered statistically significant. Graphs show the mean 6 SD or
SEM, as stated in the figure legend.
Supporting Information
Figure S1 Increased expression of CD11c on NK cells
following IL-12 treatment. Mice were injected with VC or IL-
12 (1 mg/mouse) for four consecutive days. Flow cytometric
analysis was performed on day 5 to evaluate CD11c expression on
the gated NKp46+ cells in the spleen and liver following IL-12
treatment. Percentage of CD11c expressing NK cells is indicated
in the upper right hand corner of each histogram. Shaded line
represents the isotype control.
(TIF)
Figure S2 Phenotypic characterization of cell surface
markers distinguishing CD11b+ and CD8a+ DCs in the
spleen and liver. Splenic and hepatic leukocytes were stained
with a panel of antibodies to gate DC specific populations by flow
cytometry. DCs were determined by gating on NKp462 CD11c+
Class II+ cells then further categorized into CD11b+ and CD8a+
DCs, based upon expression of CD11b and CD8a markers,
respectively. This gating strategy was utilized to enumerate specific
DC subsets.
(TIF)
Figure S3 Phenotypic characterization of cell surface
markers characterizing splenic and hepatic pDCs.
Splenic and hepatic leukocytes were stained with a panel of
antibodies to gate the pDC population by flow cytometry. The
pDCs were defined based upon NKp462 CD11c+ Class II+
B220+ mPDCA-1+ and Siglec H+ expression. This gating strategy
was utilized to enumerate pDC subsets.
(TIF)
Figure S4 Hepatic DC maturation is dependent upon
the presence of NK cells. Mice were treated with either IL-12
(1 mg/mouse) or VC i.p. for four consecutive days in C57BL/6,
SCID (which lack T cells but have NK cells present), and
IL2Rgamma(c) KO mice (which lack both T and NK cells). Multi-
color flow cyotmetric analysis was performed on gated hepatic
cDC populations. A representative histogram is shown from an
independent experiment with 2–6 mice per group and repeated 3
times. In the histogram overlays, the shaded line is the isotype
control, dashed line is the vehicle control and the solid line is with
IL-12 administration.
(TIF)
Figure S5 Co-staining of splenic and hepatic DC subsets
for antigen processing with costimulatory molecule
expression. Bulk lymphocytes from the spleen and liver were
incubated with DQ-OVA, as indicated in Material and Methods,
then co-stained with anti-CD80 antibody for flow cytometric
analysis. Shown are representative contour plots from DC subsets
from the spleen and liver from 4–8 mice/group. This has been
repeated in two independent experiments.
(TIF)
Figure S6 Altered cytokine expression from splenic and
hepatic DCs following TLR stimulation. Bulk lymphocytes
from the spleen and liver were incubated with media alone (no
treatment; no Tx), 25 mg/ml poly(I:C), 1 mg/ml LPS or 2.5 mg/
ml CpG for 18 hours. (A) Splenic DC and hepatic DC populations
were gated and intracellular IL-12p40 expression examined by
flow cytometric analysis. The graph shows the mean 6 SEM of
DC expressing IL-12p40 derived from 3 independent experiments
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Culture supernatants were collected from similar TLR-stimulated
DC cultures after 48 hours to detect IL-6 expression.
(TIF)
Figure S7 Enhanced HA T cell proliferation of specific
splenic and hepatic DC subsets following IL-12 treat-
ment. FACS-sorted purified DC populations cDC and pDC were
pulsed with 10–10 M HA peptide then cocultured for 72 hrs with
equal numbers of Cln-4 HA purified T cells in quadruplicates.
Cultures were pulsed with 1 mCi of 3H per well 18 hrs prior to
harvesting the cells onto filter mats to quantitate cell proliferation.
Data shown is expressed as HA stimulation index calculated as the
ratio of Cln-4 T cell proliferation in the presence of HA peptide-
pulsed DC to Cln-4 T cells only. Shown is the mean +/2 S.D.; ***
p,0.001, Student T test.
(TIF)
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